BFC Planning’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.28K Hold
519
– – ﹤0.01% 2477
2026
Q2
$7.86K Hold
519
– – ﹤0.01% 2485
2026
Q1
$5.66K Hold
519
– – ﹤0.01% 2264
2025
Q4
$6.71K Hold
519
– – ﹤0.01% 2238
2025
Q3
$6.71K Hold
519
– – ﹤0.01% 2088
2025
Q2
$9.24K Hold
519
– – ﹤0.01% 1851
2025
Q1
$9.25K Hold
519
– – ﹤0.01% 1798
2024
Q4
$15.5K Sell
519
-101
-16% -$2.14K ﹤0.01% 1566
2024
Q3
$9.7K Buy
+620
New +$11.2K ﹤0.01% 1766

Other funds holding NVCR

BFC Planning's NVCR Position: Q3 2026 in Review

BFC Planning held its NovoCure (NVCR) position steady in Q3 2026 at 519 shares worth $8.28K. The position accounts for ﹤0.01% of the portfolio, ranked #2477.

BFC Planning first reported a position in NVCR in Q3 2024 and has held it in 9 quarters since. The position peaked at $15.5K in Q4 2024. 185 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • BFC Planning held 519 shares of NovoCure worth $8.28K as of Q3 2026.
  • BFC Planning left its NovoCure share count unchanged in Q3 2026.
  • NovoCure made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2477 holding.
  • BFC Planning first reported a position in NovoCure in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's NovoCure position peaked at $15.5K in Q4 2024.
  • 185 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.